Abstract

The tumor suppressor gene TP53 is the most commonly mutated gene in human cancer. In addition to loss of tumor suppressor functions, mutations in TP53 promote cancer progression by altering cellular iron acquisition and metabolism. A newly identified role for TP53 in the coordination of iron homeostasis and cancer cell survival lies in the ability for TP53 to protect against ferroptosis, a form of iron-mediated cell death. The purpose of this study was to determine the extent to which TP53 mutation status affects the cellular response to ferroptosis induction. Using H1299 cells, which are null for TP53, we generated cell lines expressing either a tetracycline inducible wild-type (WT) TP53 gene, or a representative mutated TP53 gene from six exemplary “hotspot” mutations in the DNA binding domain (R273H, R248Q, R282W, R175H, G245S, and R249S). TP53 mutants (R273H, R248Q, R175H, G245S, and R249S) exhibited increased sensitivity ferroptosis compared to cells expressing WT TP53. As iron-mediated lipid peroxidation is critical for ferroptosis induction, we hypothesized that iron acquisition pathways would be upregulated in mutant TP53-expressing cells. However, only cells expressing the R248Q, R175H, and G245S TP53 mutation types exhibited statistically significant increases in spontaneous iron regulatory protein (IRP) RNA binding activity following ferroptosis activation. Moreover, changes in the expression of downstream IRP targets were inconsistent with the observed differences in sensitivity to ferroptosis. These findings reveal that canonical iron regulatory pathways are bypassed during ferroptotic cell death. These results also indicate that induction of ferroptosis may be an effective therapeutic approach for tumor cells expressing distinct TP53 mutation types.

Highlights

  • Iron is an essential, yet potentially toxic nutrient that can contribute to both the initiation and progression of cancer [1,2,3,4]

  • TP53 expression levels were variable between WT and mutant TP53-expressing subtypes, but we have previously demonstrated that even a low level induction of WT TP53 protein is sufficient to induce expression of the WT TP53 target, Cyclin Dependent Kinase Inhibitor 1A (CDKN1A) [22]

  • Additional post hoc analyses revealed that induction of R273H, R248Q, R175H, G245S, and R249S TP53 mutations significantly increased sensitivity to ferroptosis induction, as evidenced by reduced cell viability compared to the WT TP53-expressing cells following erastin treatment (Figure 1B)

Read more

Summary

Introduction

Iron is an essential, yet potentially toxic nutrient that can contribute to both the initiation and progression of cancer [1,2,3,4]. The tumor suppressor TP53 can protect against carcinogenesis by contributing to the regulation of cellular iron homeostasis [5,6,7]. Mutations in TP53 can lead to both loss of tumor suppressive functions and the acquisition of oncogenic traits, but the influence on cellular iron homeostasis has yet to be fully described. The cytosolic mRNA binding proteins, iron regulatory proteins (IRP1 and IRP2), function as key regulators of cellular iron homeostasis by coordinating iron uptake, storage, and utilization in accordance with cellular iron availability. When iron availability is limited, the binding of IRPs to iron responsive elements (IREs) within the 5 untranslated region of mRNA such as ferritin heavy chain 1 (FTH1) results in translational inhibition [8]. IRP2 is subject to proteasomal degradation, while IRP1 is regulated via the insertion of a Fe-S cluster, which prevents IRE binding [9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call